Literature DB >> 1851098

MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D.

P Briozzo1, J Badet, F Capony, I Pieri, P Montcourrier, D Barritault, H Rochefort.   

Abstract

High and low affinity receptors for basic fibroblast growth factor (bFGF) were detected by binding experiments on MCF7 breast cancer cells. These cells were stimulated for growth by physiological concentrations of bFGF. However, in contrast to endothelial cells, these MCF7 cells did not produce detectable amounts of biologically active bFGF or related heparin-binding growth factor(s) of the FGF family. In vitro, the cathepsin D (cath-D) secreted by MCF7 cells was able to digest extracellular matrix (ECM) and to release ECM-bound 125I-bFGF. When MCF7 cells were cultured on ECM containing bound bFGF, they internalized bFGF, which was slowly and partially proteolyzed in the cells. Processing occurred in acidic compartments and was inhibited by leupeptin. Pepstatin A, an inhibitor of aspartyl proteases, had no effect on the processing but reduced internalization of matrix-bound bFGF by MCF7 cells. Taken together, these results suggest a cooperation between cath-D and bFGF, by which the protease could facilitate the release of bFGF from ECM and its subsequent use by breast cancer cells and/or adjacent cells involved in angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851098     DOI: 10.1016/0014-4827(91)90362-x

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  27 in total

1.  Frequent red cell transfusions reduced vascular endothelial activation and thrombogenicity in children with sickle cell anemia and high stroke risk.

Authors:  Hyacinth I Hyacinth; Robert J Adams; Jenifer H Voeks; Jacqueline M Hibbert; Beatrice E Gee
Journal:  Am J Hematol       Date:  2013-11-28       Impact factor: 10.047

2.  Evaluation of serum cathepsin B and D in relation to clinicopathological staging of colorectal cancer.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Andrzej Wincewicz; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-07-21       Impact factor: 5.742

Review 3.  Proteolytic-antiproteolytic balance and its regulation in carcinogenesis.

Authors:  Elzbieta Skrzydlewska; Mariola Sulkowska; Mariusz Koda; Stanislaw Sulkowski
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

4.  Beneficial effects of cathepsin inhibition to prevent chemotherapy-induced intestinal mucositis.

Authors:  I Alamir; N Boukhettala; M Aziz; D Breuillé; P Déchelotte; M Coëffier
Journal:  Clin Exp Immunol       Date:  2010-08-20       Impact factor: 4.330

5.  Alpha1-antichymotrypsin and kallistatin hydrolysis by human cathepsin D.

Authors:  D C Pimenta; V C Chen; J Chao; M A Juliano; L Juliano
Journal:  J Protein Chem       Date:  2000-07

6.  Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo.

Authors:  K Menzel; M Hausmann; F Obermeier; K Schreiter; N Dunger; F Bataille; W Falk; J Scholmerich; H Herfarth; G Rogler
Journal:  Clin Exp Immunol       Date:  2006-10       Impact factor: 4.330

7.  Vasculopathy in type 2 diabetes mellitus: role of specific angiogenic modulators.

Authors:  Enas A Hamed; Madeha M Zakary; Reffat M Abdelal; Effat M Abdel Moneim
Journal:  J Physiol Biochem       Date:  2011-02-19       Impact factor: 4.158

Review 8.  Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.

Authors:  Carmen Clapp; Stéphanie Thebault; Gonzalo Martínez de la Escalera
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

Review 9.  Evaluation of cathepsin D as a prognostic factor in breast cancer.

Authors:  P M Ravdin
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

Review 10.  Cathepsin D--many functions of one aspartic protease.

Authors:  Petr Benes; Vaclav Vetvicka; Martin Fusek
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-08       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.